Gyorgi Keri

Title: Gyorgi Keri: Innovator in Platelet Derived Growth Factor Research

Introduction

Gyorgi Keri is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of medical research, particularly in the treatment of disorders related to platelet derived growth factor (PDGF). With a total of 4 patents, Keri's work focuses on developing compounds that inhibit PDGF receptor activity, which is crucial for addressing various cell proliferative disorders.

Latest Patents

Keri's latest patents revolve around compounds designed to inhibit PDGF receptor (PDGF-R) activity. These compounds not only target PDGF-R but also aim to inhibit the activity of other members of the PDGF-R super family, including Flt and KDR. The featured compounds have shown effectiveness in cell cultures, reducing PDGF-R activity and potentially treating patients suffering from disorders characterized by inappropriate PDGF-R activity. One notable compound, A10, has demonstrated the ability to inhibit the growth of tumor cells in vivo, showcasing the potential of Keri's innovations in cancer treatment.

Career Highlights

Throughout his career, Gyorgi Keri has worked with esteemed organizations such as Sugen Incorporated and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his research and contributions to medical science.

Collaborations

Keri has collaborated with notable professionals, including Klaus Peter Hirth and Laura Kay Shawver. These partnerships have played a significant role in advancing his research and the development of innovative treatments.

Conclusion

Gyorgi Keri's work in the field of platelet derived growth factor research exemplifies the impact of innovation in medical science. His patents and collaborations highlight his commitment to developing effective treatments for serious health conditions.